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A short meeting, held as an Arthur Sackler Colloquium of the United States National Academy of Sciences,
was organized by Douglas Wallace, Susan Bryant, and Peter Donovan under the heading ‘‘Therapeutic
Cloning: Where Do We Go from Here?’’ on October 8 and 9, 2007. The individual components required for
therapeutic cloning now exist. The question, therefore, is what constraints presently limit or prevent its
application to human therapy.The meeting on which this commentary is based took place
before the most recent advances in generating ES-like cells di-
rectly from adult mouse and human fibroblasts (induced pluripo-
tent cells, iPSs) (Takahashi et al., 2007; Yu et al., 2007). This
commentary focuses on nuclear reprogramming by nuclear
transfer (NT) to eggs. We have in mind that, if the mechanisms
of nuclear reprogramming by eggs and oocytes come to be un-
derstood, these could be used to significantly improve the effi-
ciency of fibroblast conversion by the iPS route.
The idea of NT to eggs (or cloning, as it is often called nowa-
days) was already outlined in 1886 by Rauber (Rauber, 1886),
who described an experiment in which the nucleus of a toad
cell was exchangedwith the nucleus of a frog egg and vice versa.
The experiment was said to have been carried out, but neither
egg developed or even divided to the two cell stage. In 1952,
Briggs and King (Briggs and King, 1952) succeeded in trans-
planting blastula nuclei to the enucleated eggs of the frog Rana
pipiens and obtained swimming larvae. In 1958 (Gurdon et al.,
1958), the first adult vertebrate was obtained by NT (cloning)
by using Xenopus laevis. Subsequently, fertile adults were ob-
tained by transplanting intestinal epithelium cell nuclei to enucle-
ated eggs, thereby generating clones of adult animals from so-
matic cell nuclei. In 1997, Dolly the sheep was reported, arising
from the transplantation of the nucleus of a cell derived from
the mammary gland of another sheep (Wilmut et al., 1997).
Finally, an adult fertile mouse was obtained by NT from a genet-
ically rearranged lymphocyte nucleus (Hochedlinger and Jae-
nisch, 2002). In parallel with these experiments, the discovery
was made of embryonic stem cells capable of indefinite prolifer-
ation in culture and of differentiation after transfer to host blasto-
cysts (Evans and Kaufman, 1981). The combination of NT in
vertebrates and ES cell derivation from blastocysts in mice laid
the foundation for the production of person-specific replace-
ment cells that would be insensitive to immunological rejection.
So what is now preventing the application of this combined
procedure to regenerative medicine in humans? The meeting
discussed constraints at several levels as well as the state of
ongoing progress toward overcoming these issues.
Legal and Ethical Constraints
Involvement of the scientist and clinician in the study and treat-
ment of the reproductive process has always resulted in conflictwith the law and the state. NT engenders intense minority oppo-
sition, primarily based on concern for the unique genetic status
and potential of the preimplantation embryo. But the basis for
this objection is challenged by the NT process. Reproductive
cloning tells us that the nucleus of a somatic cell is totipotent;
thus, there is no unique genetic status for a NT-derived egg/em-
bryo. This cell holds the potential for advancement of medical
science. While being aware of the ongoing need to engage in
the public debate about these issues, the meeting concentrated
on the way forward with the science, given the understanding
among participants that fulfilling the therapeutic potential of NT
would be the most persuasive argument.
There are different consequences of the legal opposition. Most
countries that have relevant legislation have banned NT, despite
many having approved research on embryos. The US has no
prohibitive legislation but relies on a ban on the use of federal
funding. This approach does not prevent NT, while arguably re-
sulting in a less-well-coordinated national strategy. In the UK,
a country with the most permissive legislation in this field, the
main obstacles are the complex and bureaucratic regulatory
procedures. The basis for variation in international legislation is
unclear but may relate to many possible reasons, e.g., religious,
political, or historical. To some observers, many objections seem
to be based primarily on misinformation and misplaced moral in-
dignation. Surprisingly, although there are internationally agreed
ethical principles underpinning all medical research (Declaration
of Helsinki), opposition to NT and embryo research is not based
on any consistent bioethical framework.
The fundamental basis of ethically acceptable medical re-
search is the interests of the participant. Ann Lyerly (DukeUniver-
sity, Durham, NC) presented data on the views of patients who
were asked to donate embryos to research (Lyerly and Faden,
2007). Their high level of support reflects experience elsewhere
and more closely matches public opinion than is apparent from
the political debate (Cortes et al., 2007). Consistent with other
medical research, using the views of the donors and potential
patients to reframe the debate and to guide public policy would
be an advisable way forward.
The egg is nature’s choice to reprogram a nucleus, as it has
a physiological function to complete this process on the sperm
nucleus during fertilization. Although other strategies must be
pursued, the necessity to utilize human eggs to understand the
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straint in the development of NT is the supply of human eggs.
Not surprisingly, therefore, opponents of NT have targeted the
donation process and used this as an indirect tool to stop re-
search. The international reaction to the fraudulent data pre-
sented by Korean scientists had a major negative impact on
progress in this field. Concerns about the recruitment of their
egg donors are repeatedly used as an example to further restrict
and prohibit the research, portraying both scientists and clini-
cians as unreliable. It was appropriate, therefore, that partici-
pants at the conference reviewed the events in order to learn
from past mistakes. Mildred Cho (Stanford University, Palo
Alto, CA) described the importance of the relationship between
the clinicians responsible for the care of women who donate
eggs and the scientists who undertake the laboratory experi-
ments. The distinct nature of these two roles inevitably produces
a division of responsibility that can only be successful if there is
complete trust and teamwork from all sides. Concern was ex-
pressed byGerald Schatten (University of Pittsburgh, Pittsburgh)
at the >2000 eggs used by the Korean scientists without taking
our knowledge forward in the field. Clinicians advising donors
need to be confident that each egg donated is to be used wisely.
The main issues debated in relation to egg donation concern
the physical risk for the donor and payment for donation. The
risks have been quantified based on our knowledge of the IVF
program. The associatedmorbidity andmortality are not insignif-
icant, but careful assessment of donors can reduce the risk to
ethically acceptable levels for volunteers in medical research
(Jayaprakasan et al., 2007). Although nonpatient egg donors in
the US may be paid to help infertile couples have a child, pay-
ment for eggs for research is not permitted. Kevin Eggan (Har-
vard University, Cambridge, MA) described the lack of success
of recruitment for research, despite significant investment in
advertising. In contrast, payment to all nonpatient egg donors
is not allowed in the UK, whereas the recently approved egg-
sharing scheme was acknowledged to be a possible way for-
ward. Under this scheme, selected IVF patients from whom
many eggs are aspirated agree to donate half to research. As
compensation, they receive a reduced cost for their treatment.
Different approaches may be successful in individual countries
reflecting cultural variation. Nonetheless, the underlying princi-
ples of informed consent without coercion or exploitation must
be upheld.
At this international meeting, it was clear that the variation in
legislation and regulation primarily influenceswhere the research
is being carried out, rather than the nature of the research. Prog-
ress would undoubtedly be quicker if there were to be a better
match between the funding and regulation opportunities.
Researchers are developing alternative strategies intended to
overcome the regulatory and ethical obstacles rather than ad-
dress the scientific problems. For instance, the derivation of
ES cell lines from blastomeres taken from human embryos
(Chung et al., 2008) destined for fertility treatment is designed
to overcome ethical concerns. Whether such techniques are eth-
ically more acceptable than the use of IVF embryos was chal-
lenged during discussions at the meeting. Another suggested
strategy is the genetic modification of derived embryos to re-
move implantation potential (Hurlburt, 2005), the intention being
to change the ethicist’s view of the moral status of such cells.
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Nuclear Transfers to Eggs and Oocytes
The normal process of cell differentiation is a largely unidirec-
tional and irreversible process. Soon after the blastocyst or blas-
tula stage, embryo cells become very restricted in the range of
cell types that they can form. Only in very exceptional cases
can a cell that has differentiated into one type switch to another,
with or without intervening cell division. One such well-docu-
mented example is that of the iris cells of a newt eye, which
can transform after several divisions into lens or corneal cells
(Okada, 1991). Another example of transdifferentiation cited by
Bryant (University of California, Irvine, Irvine, CA) is the regener-
ation of limbs in urodele newts. Even here, it is not certain
whether there is a true cell-type change or whether the newmus-
cle and cartilage are formed by dedifferentiation, cell division,
and redifferentiation back into the original cell type.
In contrast, somatic cell nuclear transfer (SCNT) to eggs is
efficient at making a cell depart from its chosen lineage. In Am-
phibia, the nucleus of a cell committed to the endoderm (future
intestine) lineage is able, after transplantation to an egg, to
form functional muscle and nerve in up to 30% of all NTs (Gur-
don, 1962). The sperm is a highly differentiated cell but is reprog-
rammed to be able to form every cell type in the body in 100% of
fertilized eggs. The egg is therefore themost efficient reprogram-
ming cell known.
For the purposes of cell replacement therapy, there is no need
for SCNT to lead to the formation of a complete individual. It is
often pointed out that the formation of normal sexually mature
individuals, whether frogs or mice, is achieved at a frequency
of no more than 1%–2%. But the aim of a cell replacement
therapy is not at all to produce sexually mature individuals. The
desirable outcome is in effect the reverse, i.e., to produce a ho-
mogeneous population of cells of one kind. Indeed, the success
of generating ES cells from blastocysts is about ten times greater
than the production of cloned mice from adult cells. The thera-
peutically useful route is therefore to obtain blastocyst embryos
by transplanting nuclei from readily accessible adult cells such
as skin or bone marrow; these blastocyst cells would then be
proliferated extensively and made to differentiate into the
required cell type such as heart or brain. The embryo-derived
replacement cells would then be grafted to the host requiring
replacement therapy.
The efficiency of NT decreases dramatically when nuclei of
adult or differentiated cells are used as donors. Teruhiko Wa-
kayama (RIKEN, Japan) has explored various treatments to im-
prove NT success. Exposing donor nuclei to dimethyl sulphoxide
or Trichostatin A can increase the yield of blastocysts from adult
cells by up to two to five times, but even then the yield of ES cul-
tures from adult cells is less than 10% (Wakayama et al., 2001).
Although the range of mammals that can be cloned to adult-
hood is now wide (Cibelli et al., 2007) and the methodology re-
quired differs from one species to another, until recently it was
only in the mouse that the combination of NT and ES cell deriva-
tion has been successful (Munsie et al., 2000). However, very re-
cently, dramatic success has been achieved with the Macaque
monkey (Byrne et al., 2007). Ian Wilmut (University of Edinburgh,
Edinburgh) commented that a key to the success of creating
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donor and recipient. Several laboratories have attempted to
use the Hakelien procedure (Hakelien et al., 2002) to incubate
permeabilized somatic cells in extracts of eggs or oocytes (for
example, Hansis et al., 2004), but so far no new gene activity
has been achieved with egg or oocyte extracts, possibly be-
cause these extracts have been substantially diluted compared
to the starting material.
Much interest attaches to the molecules and mechanisms of
nuclear reprogramming employed by eggs and oocytes in the
hope that these could be used, when identified, to improve the
efficiency of the Yamanaka iPS procedure (Takahashi et al.,
2007; see below). Xenopus oocytes provide an abundant source
of material and can directly activate stem cell marker genes, and
others, without cell division or protein synthesis; one candidate
reprogramming transcription factor has recently been identified
(Koziol et al., 2007). A discussion took place on whether the de-
velopmental abnormalities frequently seen in NT embryos have
a genetic or epigenetic basis. Eggan pointed out that a very care-
ful genomic analysis failed to reveal genetic changes in abnormal
NT mice, therefore favoring the view that many such abnormali-
ties may have a stable epigenetic basis (Ng and Gurdon, 2007).
This finding implies that the failure to reprogram somatic nuclei
may be due to changes inherited epigenetically over numerous
mitotic cell divisions.
Nuclear Transfer Variations Involving Eggs
Because of the obvious practical and ethical difficulties that
would accompany a supply of unfertilized human eggs, a variety
of alternative routes are being tested that nevertheless take
advantage of the reprogramming qualities of eggs as opposed
to somatic cells. One such route is to induce parthenogenetic
development of ovarian eggs. The merit of this approach is
that the parthenogenetic development of mousemeiotic oocytes
can be induced by chemical treatment and by cytochalasin to ini-
tiate development with a very high efficiency. The problem here
is that, due to crossing over during the first meiotic prophase, the
induced embryos will not have the same full complement of his-
tocompatibility genes as the (parental) oocyte donor animals.
The lack of a full set of MHC genes can lead to histoincompatible
tissue rejection. George Daley (Children’s Hospital Boston, Bos-
ton) described ingenious experiments in which he selected ES
cell lines grown from parthenogenetic embryos and showed
that these MHC-matched cells are fully compatible with the
oocyte donor when grafted to adults, thereby serving as histo-
compatible tissues for transplantation (Kim et al., 2007). Daley
pointed out that this route could lead to the creation of lines of
parthenogenetic embryonic stem cell lines (pES cells) that could
be used for transplantation to suitable (matched) recipients. How
many such lines would be needed? Theoretical calculations
argue that a high proportion of a human population could be
provided with usefully, but not fully, matched cells (for ABO
and HLA antigens) from genetically matched stocks of as few
as 150 ES cell lines (Taylor et al., 2005).
Another direction by which to avoid the practical difficulties of
human egg supply is to use, as NT recipients, aged eggs that
were not fertilized successfully in vitro. However, experience
shows that, although these eggs have been shown to have
some success in the derivation of ES cell lines in the mouse(Wakayama et al., 2006), this has not been replicated in the
human (Hall et al., 2007). ES cells can be derived efficiently
from a single cell of an eight cell mouse embryo or from polar
bodies (Wakayama et al., 2006). Another obviously attractive
idea is to use animal eggs combined with human nuclei to
generate what would be chromosomally human ES cell lines
(Beyhan et al., 2007). Apart from the likelihood of mitochondrial
incompatibility (see below), most cross-species combinations
of this kind have not developed beyond a blastocyst or early
embryo stage, probably because of incompatibility between nu-
clear genes and the gene-activating factors of eggs. Indeed,
there seems to be only one publication reporting proliferating
ES cells derived from human nuclei combined with enucleated
rabbit eggs (Chen et al., 2003). Clearly, this report requires
confirmation.
Several factors other than egg cytoplasm and the genetic
content of a nucleus were discussed that may well affect the
success of NT. Schatten pointed out that, at least in mammals,
the centriole is normally provided by the sperm. As far as we
know, there is no evidence yet to say whether the centriole of
a somatic cell fully substitutes for the sperm centriole. Recent
work of Eggan has drawn attention to the possibility that there
may be some important nonchromosomal components of
a nucleus (Egli et al., 2007). These are retained in a fertilized
egg if the egg is enucleated by removal of the mitotic spindle
and chromosomes rather than by removal of a complete nucleus
and its nucleoplasm. Lastly, Wallace emphasized the potential
importance of mitochondria, which are maternally inherited in
all vertebrates. Most forms of NT introduce cytoplasmic mito-
chondria into an egg, and subsequent recombination between
somatic and egg mitochondria (which are not necessarily identi-
cal) could be harmful (Wallace, 2007). The Wallace lab is now
engineering cell lines carrying the most common mitochondrial
sequence types, with a view to replacing the mixed mitochon-
drial populations of therapeutic cell lines with patient-matched
mitochondrial DNA.
ES Cells of Non-Egg Origin
In all cases of ES cell lines, it is believed that the proliferating cells
originate from those of the inner cell mass of a blastocyst stage
embryo. Pedersen described the establishment of proliferating
cells from the epiblast (postblastocyst) ofmouse embryos (Brons
et al., 2007) and indicated that these cells differ from blastocyst-
derived ES cells in several characteristics, such as substrate and
differentiation requirements. Another source of ES-like cells is
the spermatogonium of the mouse testis (Honda et al., 2007).
Some of these cells can proliferate indefinitely and be made to
differentiate into many different cell types. These cells are of
special interest because they originate from an adult and could
therefore be a source of patient-specific cells in humans. How-
ever, the frequency with which ES-like cells arise from this
source is extremely low. The most spectacular advance in this
area is the formation of proliferation- and differentiation-compe-
tent ES-like cells from adult skin; this work of the Yamanaka
group was represented by Kiichiro Tomoda (Takahashi et al.,
2007). Kathrin Plath (University of California, Los Angeles, Los
Angeles) also described work that confirms and extends these
results, for example by observing inactive chromosome reactiva-
tion and DNA demethylation. It is interesting that the transition
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morphology. The choice of inducing factors, and even whether
any factors at all are needed, is now under intense investigation.
It seems quite unclear, at present, why many cell divisions and
1–2 weeks are required for ES-like cells to emerge in these ex-
periments. Is there a minority cell population that can respond
to the transfected genes? Do cells have to be at a precise point
in the cell cycle to be responsive? Is a very precise combination
of factor concentrations required? Is it even possible that
a genetic change is required for ES-like cells to emerge?
Prospects
Perhaps the eventual procedure for producing patient-accept-
able therapeutically useful cells will involve a combination of all
these different procedures. The Yamanaka route for the direct
derivation of ES-like cells from adult skin or other accessible
tissues must be the preferred regime, assuming that these cells
are not more prone than other cells to becoming cancerous.
Perhaps, if we can discover the secrets of how eggs can so
efficiently reprogram somatic cell nuclei, some of these egg
molecules or mechanisms can be incorporated into the iPS route
to improve the efficiency and cell number production of thera-
peutically useful cells. The prospects for patient-specific cell
replacement seem now to have advanced very considerably in
recent time.
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